<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04112017</url>
  </required_header>
  <id_info>
    <org_study_id>LG-HACL019</org_study_id>
    <nct_id>NCT04112017</nct_id>
  </id_info>
  <brief_title>A Study of YVOIRE Y-Solution 360 for Hand Augmentation to Correct Volume Loss</brief_title>
  <official_title>A Multicenter, Randomized, No-treatment Controlled, Parallel, Evaluator-blind, Medical Device Pivotal Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 360 Injected Into Dorsal Hand for Hand Augmentation to Correct Volume Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of YVOIRE Y-Solution
      360 in the treatment of dorsal hand to correct volume loss.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Anticipated">July 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 27, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>≥ 1 grade improvement on Hand Volume Rating Scale (HVRS) as assessed by the evaluator-blinded</measure>
    <time_frame>12 weeks after treatment</time_frame>
    <description>5-grade photonumeric hand grading scale (grade 0 - grade 4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>≥ 1 grade improvement on Hand Volume Rating Scale (HVRS) as assessed by the evaluator-blinded and the treating investigator</measure>
    <time_frame>Up to 52 weeks after treatment</time_frame>
    <description>5-grade photonumeric hand grading scale (grade 0 - grade 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>≥ 1 grade improvement on Global Aesthetic Improvement Scale (GAIS) as assessed by the treating investigator and the subject</measure>
    <time_frame>Up to 52 weeks after treatment</time_frame>
    <description>5-point scale rating global aesthetic improvement in appearance (score -1 - score 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on Hand Volume Rating Scale (HVRS) as assessed by the evaluator-blinded and the treating investigator</measure>
    <time_frame>Up to 52 weeks after treatment</time_frame>
    <description>5-grade photonumeric hand grading scale (grade 0 - grade 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on Global Aesthetic Improvement Scale (GAIS) as assessed by the treating investigator and the subject</measure>
    <time_frame>Up to 52 weeks after treatment</time_frame>
    <description>5-point scale rating global aesthetic improvement in appearance (score -1 - score 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile as assessed by incidence of adverse events</measure>
    <time_frame>Up to 52 weeks after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Dorsal Hand Volume Loss</condition>
  <arm_group>
    <arm_group_label>YVOIRE Y-Solution 360</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum 5 ml including touch-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No-treatment. At 12 weeks after the assessment, treatment maximum 5 ml including touch-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YVOIRE Y-Solution 360</intervention_name>
    <description>Hyaluronic acid</description>
    <arm_group_label>YVOIRE Y-Solution 360</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 19 Years and older

          2. Hand Volume Rating Scale (HVRS) of grade 2 or 3 with both hands

          3. Participants who are willing to undergo the treatment of dorsal hand to correct volume
             loss

        Exclusion Criteria:

          1. Congenital defect, external injuries, lipodystrophy, unhealed wound, disease
             related-abnormalities, or tumors on the dorsal hands

          2. Active inflammation or infection on the dorsal hands

          3. Received anti-coagulation therapy, anti-platelet therapy, or expected to require
             repeated treatment within 2 weeks prior to visit 2 (randomization)

          4. Had locally applied ointments (steroid, retinoid, anti-wrinkle production, tanning, or
             any other form of irritating product) or expected to require repeated treatment within
             4 weeks prior to visit 2 (randomization)

          5. Received immuno-suppressive medication including systemic glucocorticoids or expected
             to require repeated treatment within 8 weeks prior to visit 2 (randomization)

          6. Received NSAIDs, Vitamin E, or expected to require repeated treatment within 1 week
             prior to visit 2 (randomization)

          7. Had dermal filler injections (HA, CaHA, silicon, PAAG, PMMA etc.), Botulinum toxin
             therapy, adipose tissue transplantation, or esthetic surgery within 12 months prior to
             visit 2 (randomization)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Soonchunhyang University</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyalunic acid</keyword>
  <keyword>Filler</keyword>
  <keyword>Dorsal hand</keyword>
  <keyword>Medical device</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

